Literature DB >> 15480663

Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology.

Antonia M S Müller1, Gabriele Ihorst, Roland Mertelsmann, Monika Engelhardt.   

Abstract

While for most cancers incidence and mortality are decreasing, those of non-Hodgkin's lymphoma (NHL) are steadily increasing. Research to define reasons for this increase is extensive, but has not yet resolved them. We have conducted a literature analysis on trends regarding changes in the incidence, geographic distribution, and etiologic factors of NHL. From our own and previous analyses, an increasing NHL incidence at a rate of 3-4% per year was observed for the 1970s and 1980s. This stabilized in the 1990s, nevertheless still with an annual rise of 1-2%, resulting in almost a doubling of the NHL incidence. This rise has been noted worldwide, particularly in elderly persons >55 years. Concerning gender subgroups, a male predominance throughout all age groups is apparent. Although the NHL incidence has historically been higher in whites than blacks, disproportional increases have recently been observed in the latter group. Increases in high-grade NHL and extranodal disease are predominant. Differences in geographic distribution are striking for follicular lymphoma, which is more common in Western countries than elsewhere. Asians have higher rates of aggressive NHL, T-cell lymphomas, and extranodal disease. In the Middle East, high rates of intestinal extranodal disease are observed, whereas in Africa, endemic Burkitt's lymphoma accounts for a substantial proportion. Risks for developing NHL include immunosuppression and a causal link between infectious agents, and lymphomagenesis has also been determined, particularly for human T-cell leukemia/lymphoma virus type 1 (HTLV-1), Epstein-Barr virus (EBV), and Helicobacter pylori infections. Exposure to environmental agents and occupational risks have been studied; however, their significance is as yet uncertain.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15480663     DOI: 10.1007/s00277-004-0939-7

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  136 in total

1.  Transcription factor CCAAT/enhancer-binding protein alpha and critical circadian clock downstream target gene PER2 are highly deregulated in diffuse large B-cell lymphoma.

Authors:  Nils H Thoennissen; Gabriela B Thoennissen; Sam Abbassi; Shayan Nabavi-Nouis; Tim Sauer; Ngan B Doan; Sigal Gery; Carsten Müller-Tidow; Jonathan W Said; H Phillip Koeffler
Journal:  Leuk Lymphoma       Date:  2012-02-21

2.  Toxicities and outcomes among septuagenarians and octogenarians with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy.

Authors:  Scott F Huntington; Mahsa S Talbott; John P Greer; David S Morgan; Nishitha Reddy
Journal:  Leuk Lymphoma       Date:  2012-03-01

3.  Use of IGK gene rearrangement analysis for clonality assessment of lymphoid malignancies: a single center experience.

Authors:  Claudia Mannu; Anna Gazzola; Francesco Bacci; Elena Sabattini; Carlo Sagramoso; Fernando Roncolato; Maura Rossi; Maria Antonella Laginestra; Maria Rosaria Sapienza; Claudio Agostinelli; Antonio De Leo; Milena Piccioli; Simona Righi; Patrizia Artioli; Luigi Chilli; Gianpaolo Da Pozzo; Giuseppe De Biase; Federica Sandri; Stefano A Pileri; Pier Paolo Piccaluga
Journal:  Am J Blood Res       Date:  2011-09-12

4.  A case-control study of ultraviolet radiation exposure, vitamin D, and lymphoma risk in adults.

Authors:  Jennifer L Kelly; Jonathan W Friedberg; Laura M Calvi; Edwin van Wijngaarden; Susan G Fisher
Journal:  Cancer Causes Control       Date:  2010-04-07       Impact factor: 2.506

5.  A prospective analysis of blood donation history and risk of non-Hodgkin lymphoma.

Authors:  Kazusa Ishii; Brenda M Birmann; Xuehong Zhang; Edward Giovannucci; Kimberly A Bertrand
Journal:  Leuk Lymphoma       Date:  2015-10-16

6.  Contributions of Subtypes of Non-Hodgkin Lymphoma to Mortality Trends.

Authors:  Nadia Howlader; Lindsay M Morton; Eric J Feuer; Caroline Besson; Eric A Engels
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-10-15       Impact factor: 4.254

7.  Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001.

Authors:  Lindsay M Morton; Sophia S Wang; Susan S Devesa; Patricia Hartge; Dennis D Weisenburger; Martha S Linet
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

8.  Clinical Significance of TIPE2 Protein Upregulation in Non-Hodgkin's Lymphoma.

Authors:  Chunyan Hao; Na Zhang; Minghong Geng; Qing Ren; Yan Li; Yan Wang; Youhai H Chen; Suxia Liu
Journal:  J Histochem Cytochem       Date:  2016-09       Impact factor: 2.479

9.  T-cell immunoglobulin- and mucin-domain-containing molecule 3 genetic variants and HIV+ non-Hodgkin lymphomas.

Authors:  Haihan Song; Shaolin Ma; Zhanshan Cha; Lei Chen; Danian Tong; Lan Ma; Weiguo Song; Jianwen Bai
Journal:  Inflammation       Date:  2013-08       Impact factor: 4.092

10.  Rituximab for non-Hodgkin's lymphoma: a story of rapid success in translation.

Authors:  Andrew M Harrison; Nassir M Thalji; Alexandra J Greenberg; Carmen J Tapia; Anthony J Windebank
Journal:  Clin Transl Sci       Date:  2013-10-03       Impact factor: 4.689

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.